Genelux (GNLX) Projected to Post Quarterly Earnings on Tuesday

Genelux (NASDAQ:GNLX) is expected to be posting its results before the market opens on Tuesday, May 5th. Analysts expect Genelux to post earnings of ($0.18) per share and revenue of $0.0070 million for the quarter.

Genelux (NASDAQ:GNLX) last issued its quarterly earnings data on Thursday, March 19th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.02). The firm had revenue of $0.01 million during the quarter. On average, analysts expect Genelux to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Genelux Price Performance

Genelux stock opened at $2.74 on Monday. Genelux has a 1-year low of $2.26 and a 1-year high of $8.53. The business has a fifty day moving average price of $2.64 and a 200-day moving average price of $3.81. The stock has a market capitalization of $122.77 million, a price-to-earnings ratio of -3.19 and a beta of 0.51.

Insider Buying and Selling

In other Genelux news, Director John Thomas sold 10,000 shares of Genelux stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $2.90, for a total transaction of $29,000.00. Following the completion of the sale, the director owned 482,784 shares of the company’s stock, valued at approximately $1,400,073.60. The trade was a 2.03% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 8.80% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Goldman Sachs Group Inc. lifted its holdings in shares of Genelux by 451.2% during the fourth quarter. Goldman Sachs Group Inc. now owns 183,807 shares of the company’s stock worth $801,000 after purchasing an additional 150,463 shares during the period. 683 Capital Management LLC purchased a new stake in Genelux in the fourth quarter valued at approximately $572,000. Marshall Wace LLP increased its holdings in Genelux by 312.3% in the 4th quarter. Marshall Wace LLP now owns 139,148 shares of the company’s stock worth $607,000 after buying an additional 105,402 shares during the period. Millennium Management LLC acquired a new position in Genelux in the 4th quarter worth approximately $455,000. Finally, Osaic Holdings Inc. raised its position in Genelux by 1,911.4% during the 2nd quarter. Osaic Holdings Inc. now owns 105,016 shares of the company’s stock worth $301,000 after buying an additional 99,795 shares during the last quarter. 37.33% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. Benchmark lowered their price target on Genelux from $23.00 to $20.00 and set a “speculative buy” rating for the company in a report on Friday, March 20th. HC Wainwright restated a “buy” rating on shares of Genelux in a report on Monday, January 5th. Wall Street Zen lowered shares of Genelux from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Genelux in a research note on Tuesday, April 21st. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $18.00.

Genelux Company Profile

Genelux Corporation (NASDAQ:GNLX) is a clinical-stage biotechnology company focused on the development of oncolytic virus immunotherapies. Built on a proprietary vaccinia virus platform, the company’s programs are designed to selectively infect and destroy cancer cells while stimulating a systemic immune response. Genelux’s lead candidate, pexastimogene devacirepvec (GL-ONC1), is being evaluated in multiple indications, including peritoneal malignancies and head and neck cancers, where it is administered either intraperitoneally or systemically depending on the trial design.

Genelux’s pipeline leverages its experience with the GL-ONC1 construct to explore combination strategies with chemotherapy and immuno-oncology agents.